GB201621183D0 - Clopidogrel for use in the treatment of benign prostatic hyperplasia - Google Patents

Clopidogrel for use in the treatment of benign prostatic hyperplasia

Info

Publication number
GB201621183D0
GB201621183D0 GBGB1621183.1A GB201621183A GB201621183D0 GB 201621183 D0 GB201621183 D0 GB 201621183D0 GB 201621183 A GB201621183 A GB 201621183A GB 201621183 D0 GB201621183 D0 GB 201621183D0
Authority
GB
United Kingdom
Prior art keywords
clopidogrel
treatment
benign prostatic
prostatic hyperplasia
hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB1621183.1A
Other versions
GB2541348A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skillpharm Kft
Original Assignee
Skillpharm Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skillpharm Kft filed Critical Skillpharm Kft
Publication of GB201621183D0 publication Critical patent/GB201621183D0/en
Publication of GB2541348A publication Critical patent/GB2541348A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1621183.1A 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia Pending GB2541348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1400294A HUP1400294A2 (en) 2014-06-13 2014-06-13 Novel application of clopidogrel
PCT/HU2015/000053 WO2015189650A1 (en) 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
GB201621183D0 true GB201621183D0 (en) 2017-01-25
GB2541348A GB2541348A (en) 2017-02-15

Family

ID=89991514

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1621183.1A Pending GB2541348A (en) 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia

Country Status (3)

Country Link
GB (1) GB2541348A (en)
HU (1) HUP1400294A2 (en)
WO (1) WO2015189650A1 (en)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (en) 1982-07-13 1986-05-16 Sanofi Sa NOVEL THIENO (3, 2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION
FR2623810B2 (en) 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for use in the treatment of benign prostatic hyperplasia
FR2744918B1 (en) 1996-02-19 1998-05-07 Sanofi Sa NEW COMBINATIONS OF ACTIVE INGREDIENTS CONTAINING THIENO (3,2-C) PYRIDINE DERIVATIVE AND AN ANTITHROMBOTIC
WO1999042488A1 (en) 1998-02-20 1999-08-26 Vanson, Inc. Composition and method for reducing transpiration in plants
ZA991319B (en) 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
FR2779726B1 (en) 1998-06-15 2001-05-18 Sanofi Sa POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE
CN1343128B (en) 1999-03-17 2010-04-21 第一制药株式会社 Medicinal compositions
WO2001030324A2 (en) * 1999-10-27 2001-05-03 Aufsess Joachim G Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
ATE518537T1 (en) 2002-02-07 2011-08-15 Univ Tennessee Res Foundation SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) FOR THE TREATMENT OF BENIGUS PROSTATE HYPERPLASIA
GB2393181A (en) 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
DE10305984A1 (en) 2003-02-13 2004-09-02 Helm Ag Salts of organic acids with clopidogrel and their use in the manufacture of pharmaceutical formulations
WO2005070464A2 (en) 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
EP1756116A1 (en) 2004-04-20 2007-02-28 Sanofi-Aventis Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide
KR20070009851A (en) 2005-07-14 2007-01-19 씨제이 주식회사 Pharmaceutical compositions containing clopidogrel bisulfate
KR20070044323A (en) 2005-10-24 2007-04-27 에스케이케미칼주식회사 Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
IS2385B (en) 2006-02-10 2008-07-15 Actavis Group Hf. Clopidogrel bisulfate pharmaceutical compositions
DE202006020892U1 (en) 2006-04-13 2010-10-21 Riemser Arzneimittel Ag Partial glycerides as lubricants for pharmaceutical compositions containing thieno [3,2-c] pyridine derivatives
AT506095A1 (en) 2007-12-03 2009-06-15 Volopharm Gmbh USE OF PROTEASES
ATE530172T1 (en) 2008-02-26 2011-11-15 Lesvi Laboratorios Sl PHARMACEUTICAL FORMULATIONS CONTAINING CLOPIDOGREL
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
MY171343A (en) 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
WO2014014177A1 (en) 2012-07-18 2014-01-23 조선대학교 산학협력단 Composition comprising dendropanax morbifera extract or compound derived therefrom as active ingredient for preventing and treating benign prostatic hyperplasia

Also Published As

Publication number Publication date
HUP1400294A2 (en) 2015-12-28
WO2015189650A1 (en) 2015-12-17
GB2541348A (en) 2017-02-15

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
HK1256283A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumours
IL276733A (en) Use of eribulin in the treatment of cancer
IL248767B (en) Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer
HUE054137T2 (en) Nx-1207 for use in methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
IL251903A0 (en) Apilimod for use in the treatment of colorectal cancer
IL250484A0 (en) Heterobicyclic cpmpounds and their use for the treatment of tuberculosis
IL263804A (en) Wnt inhibitors for use in the treatment of fibrosis
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
GB201621183D0 (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
GB201700061D0 (en) Acanthospermum hispidum composition for the treatment of cancer and methods for its manufacture